AngioDynamics, Inc. (NASDAQ:ANGO) saw an uptick in trading volume on Friday . 928,857 shares traded hands during mid-day trading, an increase of 378% from the previous session’s volume of 194,208 shares.The stock last traded at $17.65 and had previously closed at $17.03.

A number of research firms recently weighed in on ANGO. Canaccord Genuity restated a “hold” rating and issued a $16.50 price target on shares of AngioDynamics in a research note on Wednesday, May 31st. KeyCorp restated a “hold” rating on shares of AngioDynamics in a research note on Friday, August 25th. Cantor Fitzgerald lifted their price target on AngioDynamics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Tuesday, July 4th. Zacks Investment Research downgraded AngioDynamics from a “hold” rating to a “sell” rating in a research note on Thursday, July 20th. Finally, BidaskClub downgraded AngioDynamics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. AngioDynamics currently has an average rating of “Hold” and a consensus target price of $18.50.

The firm’s 50 day moving average price is $16.48 and its 200-day moving average price is $16.22. The firm has a market cap of $645.64 million, a PE ratio of 128.83 and a beta of 1.13.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 18th. The medical instruments supplier reported $0.19 EPS for the quarter, beating the consensus estimate of $0.16 by $0.03. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The firm had revenue of $86.90 million for the quarter, compared to analysts’ expectations of $90.72 million. During the same period last year, the firm earned $0.19 EPS. The firm’s revenue was down 7.0% compared to the same quarter last year. Analysts anticipate that AngioDynamics, Inc. will post $0.67 EPS for the current year.

In other news, CEO James C. Clemmer purchased 5,000 shares of the firm’s stock in a transaction on Friday, July 21st. The stock was purchased at an average cost of $15.79 per share, with a total value of $78,950.00. Following the purchase, the chief executive officer now owns 86,683 shares in the company, valued at approximately $1,368,724.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James C. Clemmer purchased 20,000 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were purchased at an average cost of $15.64 per share, with a total value of $312,800.00. Following the completion of the purchase, the chief executive officer now owns 86,683 shares in the company, valued at approximately $1,355,722.12. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 25,316 shares of company stock worth $396,806. 1.88% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of the stock. State of Alaska Department of Revenue raised its position in shares of AngioDynamics by 91.7% in the second quarter. State of Alaska Department of Revenue now owns 6,768 shares of the medical instruments supplier’s stock worth $109,000 after buying an additional 3,238 shares during the last quarter. Teachers Retirement System of The State of Kentucky raised its position in shares of AngioDynamics by 77.5% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 7,100 shares of the medical instruments supplier’s stock worth $123,000 after buying an additional 3,100 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in shares of AngioDynamics by 3.0% in the first quarter. Municipal Employees Retirement System of Michigan now owns 7,200 shares of the medical instruments supplier’s stock worth $125,000 after buying an additional 210 shares during the last quarter. Mason Street Advisors LLC raised its position in shares of AngioDynamics by 8.5% in the first quarter. Mason Street Advisors LLC now owns 7,470 shares of the medical instruments supplier’s stock worth $130,000 after buying an additional 584 shares during the last quarter. Finally, Acrospire Investment Management LLC raised its position in shares of AngioDynamics by 3.7% in the second quarter. Acrospire Investment Management LLC now owns 8,915 shares of the medical instruments supplier’s stock worth $145,000 after buying an additional 317 shares during the last quarter. 95.80% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “AngioDynamics, Inc. (ANGO) Sees Large Volume Increase” was posted by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/02/angiodynamics-inc-ango-sees-large-volume-increase-3.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.